Abstract
Inferring the relative strength (i.e., the ratio of reproduction numbers, ℛvar/ℛwt) and relative speed (i.e., the difference between growth rates, rvar −rwt) of new SARS-CoV-2 variants compared to their wild types is critical to predicting and controlling the course of the current pandemic. Multiple studies have estimated the relative strength of new variants from the observed relative speed, but they typically neglect the possibility that the new variants have different generation intervals (i.e., time between infection and transmission), which determines the relationship between relative strength and speed. Notably, the increasingly predominant B.1.1.7 variant may have a longer infectious period (and therefore, a longer generation interval) than prior dominant lineages. Here, we explore how differences in generation intervals between a new variant and the wild type affect the relationship between relative strength and speed. We use simulations to show how neglecting these differences can lead to biases in estimates of relative strength in practice and to illustrate how such biases can be assessed. Finally, we discuss implications for control: if new variants have longer generation intervals then speed-like interventions such as contact tracing become more effective, whereas strength-like interventions such as social distancing become less effective.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
B.M.B. was supported by the Natural Sciences and Engineering Research Council of Canada. J.D. was supported by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, and the Michael G. DeGroote Institute for Infectious Disease Research. J.S.W. was supported by the National Science Foundation (2032082). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB required for this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and code are stored in a publicly available GitHub repository (https://github.com/parksw3/newvariant)
